Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib and Berberine in Advanced EGFR-Mutated NSCLC
NCT03486496Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of berberine in non-small cell lung cancer (NSCLC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-Free Survival at 30 months. Status: unknown.
02
Drugs
berberine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03486496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486496.